However, these drugs have drawbacks, including low stability in the body, short half-lives, poor membrane permeability, complex manufacturing processes, and high costs
[11] [12] Simultaneously, obesity drives hepatic fat accumulation through increased free fatty acid delivery to the liver and impaired lipid metabolism
GLP-1s aren't a reason to cut out dessert entirely
While most patients do not experience mood changes, higher-risk groups include: History of depression, anxiety, or bipolar disorder ADHD or dopamine-sensitive conditions Very rapid weight loss Inadequate protein or electrolyte intake Poor sleep quality Lower risk is associated with: Slow dose titration Adequate nutrition Stable blood sugar Good sleep hygiene What Clinicians and Patients Can Do Before Starting a GLP-1 Screen for mood disorders Set expectations about appetite changes Discuss minimum nutrition goals During Treatment Monitor caloric intake (not just weight) Prioritize protein and hydration Watch for glucose variability Adjust dose slowly If Irritability Appears Assess nutrition first Evaluate sleep and reflux Consider dose adjustment Monitor mood over time In many cases, simple nutritional adjustments or slower titration resolve symptoms without stopping the medication
Unlike semaglutide, which targets only GLP-1 receptors, tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors
China Market Analysis GLP-1 drugs are helping China expand its domestic pharmaceutical industry and global biotech influence via rapid market growth, massive manufacturing investments, and lucrative cross-border licensing deals
